Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients

NCT04979988 · clinicaltrials.gov ↗

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

ALK-positive Non-small-cell Lung Cancer

Interventions

DRUG: Lortlatinib

Sponsor

Pfizer